183 related articles for article (PubMed ID: 31079064)
1. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
John N; Carroll A; Brownlee WJ; Chataway J
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1376-1378. PubMed ID: 31079064
[No Abstract] [Full Text] [Related]
2. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
Piena MA; Heisen M; Wormhoudt LW; Wingerden JV; Frequin STFM; Uitdehaag BMJ
J Med Econ; 2018 Oct; 21(10):968-976. PubMed ID: 29911917
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
[TBL] [Abstract][Full Text] [Related]
4. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
Dubey D; Cano CA; Stüve O
Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S; Schmidt R; Straeten FA; Pul R; Kleinschnitz C; Wieshuber M; Lee DH; Linker RA; Doerck S; Straeten V; Windhagen S; Pawlitzki M; Aufenberg C; Lang M; Eienbroeker C; Tackenberg B; Limmroth V; Wildemann B; Haas J; Klotz L; Wiendl H; Ruck T; Meuth SG
J Neurol; 2019 Jan; 266(1):165-173. PubMed ID: 30446966
[TBL] [Abstract][Full Text] [Related]
6. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
[No Abstract] [Full Text] [Related]
7. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L
Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
[TBL] [Abstract][Full Text] [Related]
8. Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
Fiander MDJ; Bhan V; Stewart SA; Parks NE
Can J Neurol Sci; 2019 Jul; 46(4):455-458. PubMed ID: 31113500
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
Puz P; Lasek-Bal A
Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
[TBL] [Abstract][Full Text] [Related]
11. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
13. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
14. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
Montgomery SM; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
[TBL] [Abstract][Full Text] [Related]
15. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
[TBL] [Abstract][Full Text] [Related]
16. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
Noon KM; Montgomery SM; Adlard NE; Kroes MA
J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal real-life comparison study of natalizumab and fingolimod.
Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F
Ann Neurol; 2016 Jun; 79(6):950-8. PubMed ID: 27038238
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
